Sacituzumab Govitecan and Atezolizumab Treatment for Rare Genitourinary Tumors

This clinical trial is focused on finding better treatment options for people with rare types of genitourinary (GU) cancers, including certain aggressive bladder, urinary tract, kidney, and penile cancers. These rare cancers often have a more severe progression and lack established treatments, making them challenging to manage. The study investigates the effectiveness of a drug called sacituzumab govitecan (SG), used alone or together with another drug, atezolizumab, in patients who have these specific types of cancers. The trial aims to improve the response rate to these treatments, potentially offering new hope for patients with these difficult-to-treat conditions. Participants in the study must be adults with advanced or metastatic forms of these rare cancers. The study administers the treatments intravenously; SG is given on the first and eighth day of each 21-day cycle, while atezolizumab is given on the first day of each cycle. Participants who have not previously received certain types of immunotherapy may receive both drugs. The study will continue to treat participants until their cancer shows signs of progression or they experience severe side effects, for up to five years. This research could lead to more effective therapies for these rare and aggressive cancers, potentially improving outcomes for those affected.